NYSE:ZYME (Canada)  
Zymeworks BC Inc logo

Zymeworks BC Inc

$ 7.58 -0.15 (-1.94%) 10:08 PM EST
P/E:
At Loss
P/B:
1.97
Market Cap:
$ 467.64M
Enterprise V:
$ 257.82M
Volume:
1.06M
Avg Vol (2M):
1.19M
Also Trade In:
Volume:
1.06M
Market Cap $:
467.64M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.19M
Enterprise Value $:
257.82M
PB Ratio:
1.97
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Name Current Vs Industry Vs History
Cash-To-Debt 7.56
Equity-to-Asset 0.6
Debt-to-Equity 0.14
Debt-to-EBITDA -0.14
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.64
Distress
Grey
Safe
Beneish M-Score -2.65
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 33.66
9-Day RSI 46.21
14-Day RSI 51.46
6-1 Month Momentum % 4.15
12-1 Month Momentum % -65.27

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.28
Quick Ratio 3.28
Cash Ratio 3.02
Days Sales Outstanding 88.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -13.4

Financials (Next Earnings Date:2023-02-24 Est.)

ZYME's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with NYSE:ZYME

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 31.623
EPS (TTM) ($) -4.36
Beta 0.98
Volatility % 63.71
14-Day RSI 51.46
14-Day ATR ($) 0.558542
20-Day SMA ($) 7.893
12-1 Month Momentum % -65.27
52-Week Range ($) 4.11 - 20.425
Shares Outstanding (Mil) 61.69

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Zymeworks BC Inc Filings

Document Form Filing Date
No Filing Data

Zymeworks BC Inc Analysis

Share your research

Headlines

See More
No news.